Yacktman Asset Management LP Has $30.93 Million Stake in Embecta Corp. $EMBC

Yacktman Asset Management LP reduced its holdings in shares of Embecta Corp. (NASDAQ:EMBC) by 7.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,191,706 shares of the company’s stock after selling 181,680 shares during the period. Yacktman Asset Management LP owned 3.75% of Embecta worth $30,925,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Summit Global Investments bought a new stake in shares of Embecta during the 3rd quarter valued at about $161,000. SummerHaven Investment Management LLC lifted its stake in Embecta by 19.2% in the third quarter. SummerHaven Investment Management LLC now owns 79,043 shares of the company’s stock valued at $1,115,000 after buying an additional 12,730 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of Embecta by 365.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 372,451 shares of the company’s stock worth $5,255,000 after buying an additional 292,477 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Embecta during the 3rd quarter worth approximately $173,000. Finally, Inspire Advisors LLC increased its stake in shares of Embecta by 8.6% in the 3rd quarter. Inspire Advisors LLC now owns 38,006 shares of the company’s stock valued at $536,000 after acquiring an additional 3,007 shares in the last quarter. 93.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on EMBC shares. Zacks Research cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 27th. Finally, BTIG Research reissued a “buy” rating on shares of Embecta in a research report on Tuesday, November 25th. One research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $18.50.

Embecta Price Performance

EMBC opened at $10.61 on Monday. Embecta Corp. has a 1 year low of $9.20 and a 1 year high of $18.58. The company has a market capitalization of $628.22 million, a price-to-earnings ratio of 6.51 and a beta of 1.11. The firm’s fifty day moving average price is $12.00 and its two-hundred day moving average price is $12.97.

Embecta (NASDAQ:EMBC) last announced its earnings results on Tuesday, November 25th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.46 by $0.04. Embecta had a net margin of 8.83% and a negative return on equity of 24.62%. The company had revenue of $263.30 million during the quarter, compared to the consensus estimate of $265.66 million. During the same quarter in the prior year, the company posted $0.45 earnings per share. The firm’s revenue for the quarter was down 7.7% on a year-over-year basis. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Embecta Corp. will post 2.85 EPS for the current year.

Embecta Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Friday, December 5th were paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 5.7%. The ex-dividend date was Friday, December 5th. Embecta’s payout ratio is presently 36.81%.

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.